Canaccord Genuity initiated coverage of BillionToOne Inc. (NASDAQ: BLLN) with a Buy rating. The investment firm established a price target of $120.00.
Analysts cited the company's proprietary technology as a key differentiator for its prenatal and oncology portfolios. BillionToOne achieved GAAP profitability at an earlier stage than its industry peers.
The firm expects sustained growth across all business franchises following exceptional recent performance. This initiation follows a second-quarter earnings report that surpassed market expectations.